TYRO3 Kinase Assay Kit

Catalog #
79593
$535 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

TYRO3 is a member of the TAM receptor kinases and plays an important role in cell proliferation/survival, adhesion/migration, and regulation of inflammatory cytokine release. Along with other members of this family, Axl and c-Mer (MERTK), TYRO3 is part of an emerging class of innate immune checkpoints participating in anti-tumoral immunity. Thus, it has been suggested that TYRO3 inhibition could be a promising immunotherapeutic approach in cancer treatment. The TYRO3 Assay Kit is designed to measure TYRO3 activity for screening and profiling applications using Kinase-Glo® MAX as a detection reagent.

Need us to run inhibitor screens or profile your compounds against TYRO3? Check out our Kinase Screening Services.

Synonyms
TYRO3, TYRO-3, BYK, RSE, Dtk, Sky, Tif, Brt
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Supplied As
The TYRO3 Assay Kit comes in a convenient 96-well format, with enough purified recombinant TYRO3 enzyme, TYRO3 substrate peptide, ATP and kinase assay buffer for 100 enzyme reactions.
Materials Required But Not Supplied

• Kinase-Glo MAX (Promega #V6071) 
• Dithiothreitol (DTT, 1 M; optional) 
• Microplate reader capable of reading luminescence 
• Adjustable micropipettor and sterile tips
• 30°C incubator 

Format

Assay Kit Components

UniProt #
Q06418
Background

TAM receptor protein tyrosine kinase TYRO3 is a ubiquitylation substrate for CBL-B and essential regulator of immune homeostasis. Deregulation of TAM signaling has been linked to the pathogenesis of autoimmune, inflammatory, and infectious diseases. TAM receptors have also been associated with cancer development and progression. In a cancer setting, TYRO3 has a dual regulatory role, controlling the initiation and progression of tumor development as well as the associated anti-tumor responses of diverse immune cells. Thus, modulation of TYRO3 has emerged as a potential novel strategy for cancer treatment.

TYRO3 inhibition or degradation plays a significant role in NK cell activation. Treatment of NK cells with a small molecule, a TAM kinase inhibitor, conferred therapeutic potential by efficiently enhancing anti-metastatic NK cell activity in vivo. The TAM inhibitor markedly reduced NK-dependent mammary cancer and melanoma metastases. TAM/CBL-B inhibitory pathway shows a possibility to develop new therapies that awakens the innate immune system to kill cancer metastases.

References

Akalu, Y.T., et. al. Immunological Reviews 276:165-177 (2017)